Trial-Results center  
Clinical trial results database in Heart and vessels Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

CABG surgery - cholesterol lowering intervention - preoperative statins


Related trials

JUPITER, 2008 - rosuvastatin vs placebo

Song, 2008 - vs

SAGE, 2007 - atorvastatin high dose vs pravastatin

METEOR, 2007 - rosuvastatin vs placebo

CORONA, 2007 - rosuvastatin vs placebo

Chello et al., 2006 - preoperative atorvastatin vs placebo

ASPEN, 2006 - atorvastatin vs placebo

SPARCL, 2006 - atorvastatin vs placebo

Patti et al., 2006 - preoperative atorvastatin vs placebo

MEGA, 2006 - pravastatin vs control

IDEAL, 2005 - atorvastatin high dose vs simvastatin

Vascular basis, 2005 - atorvastatin high dose vs lovastatin

TNT, 2005 - atorvastatin high dose vs atorvastatin

PACT, 2004 - pravastatin vs placebo

A to Z, 2004 - simvastatin vs placebo

ESTABLISH, 2004 - atorvastatin vs usual care

REVERSAL, 2004 - atorvastatin high dose vs pravastatin

HPS (sub groups), 2004 - simvastatin vs placebo

CARDS, 2004 - atorvastatin vs placebo

PACT, 2004 - pravastatin vs placebo

ASCOT, 2003 - atorvastatin vs placebo

LIPS (sub groups), 2002 - fluvastatin vs placebo

ALLHAT, 2002 - pravastatin vs usual care

PTT, 2002 - pravastatin vs usual care

PROSPER, 2002 - pravastatin vs placebo



See also:

  • All CABG surgery clinical trials
  • All clinical trials of cholesterol lowering intervention
  • All clinical trials of preoperative atorvastatin
  •  
     Chello et al. study, 2006 TRC7245 
    download pdf: preoperative atorvastatin | cholesterol lowering intervention for CABG surgery

    Treatments

    Studied treatment preoperative atorvastatin 20 mg/d, started 3 wks before surgery
    Control treatment placebo

    Patients

    Patients elective CABG

    Method and design

    Randomized effectives 20 / 20 (studied vs. control)
    Blinding double blind
    Follow-up duration 7 days


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    atrial fibrillation

    2 / 20
    5 / 20
    0,40 [0,09;1,83]

    myocardial infarction (fatal and non fatal)

    0 / 20
    0 / 20
    classic 1,00 [0,00;246,89]

    All cause death

    0 / 20
    0 / 20
    classic 1,00 [0,00;246,89]

    stroke (fatal and non fatal)

    0 / 20
    0 / 20
    classic 1,00 [0,00;246,89]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    atrial fibrillation 2 / 20 (10,0%) 5 / 20 (25,0%) 0,40 [0,09;1,83]  
    myocardial infarction (fatal and non fatal) 0 / 20 (2,5%) 0 / 20 (2,5%) 1,00 [0,02;47,98]  
    All cause death 0 / 20 (2,5%) 0 / 20 (2,5%) 1,00 [0,02;47,98]  
    stroke (fatal and non fatal) 0 / 20 (2,5%) 0 / 20 (2,5%) 1,00 [0,02;47,98]  
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction (for a follow-up of 7 days)
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    atrial fibrillation 10,00% 25,00% -15,00%

    Meta-analysis of all similar trials:

    cholesterol lowering intervention in CABG surgery for preoperative statins



    Reference(s)

    TrialResults-center ID TRC7245
    Trials register # NA
    • Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agrò F, Carassiti M, Covino E. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery.. Crit Care Med 2006;34:660-7
      Pubmed | Hubmed | Fulltext

    (c) 2004-2016 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100Heart and vessels